Novartis AG NVS

Novartis AG es una empresa farmacéutica con sede en Suiza. La compañía desarrolla, fabrica y comercializa medicamentos con receta de marca y genéricos, ingredientes farmacéuticos activos (API), biosimilares y productos oftálmicos. La compañía utiliza la ciencia y tecnologías digitales para tratamientos en áreas de enfermedades como inmunología, dermatología, cáncer, oftalmología, neurociencia, respiratoria, cardiovascular, renal y metabolismo. Las actividades comerciales de la compañía se dividen en dos segmentos: Medicamentos Innovadores, que incluye medicamentos innovadores con patente protegida para la presión arterial, cáncer y otras dolencias, y Sandoz, que incluye productos farmacéuticos genéricos y biosimilares.

Con 7 acciones de NVS (USD 979,72) habrías recibido USD 33,18 en dividendos en los últimos 12 meses.

• GlobeNewswire Inc. 5 oct

  Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026

  Sironax, a clinical-stage biotechnology company, has been recognized by Fierce Biotech as one of the 15 most innovative and promising private biotech companies of 2026. The company is advancing clinical-stage programs including SIR2501 (SARM1 inhibitor), SIR4156 (NAMPT activator), and SIR9900 (RIPK1 inhibitor) for neurodegenerative, metabolic, inflammatory, and immunological diseases. Sironax recently acquired a brain delivery platform to address blood-brain barrier challenges.

  

• Zacks Investment Research 5 oct

  Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

  The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.

  

• Zacks Investment Research 2 oct

  Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

  Agios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success.

  

• GlobeNewswire Inc. 2 oct

  Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity

  Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.

  

• GlobeNewswire Inc. 1 oct

  Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights

  Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.